Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa and ferric carboxymaltose for chemotherapy-induced anemia in breast cancer
2011-001664-22Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2011
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric carboxymaltose and darbepoetin alfa in chemotherapy-induced anaemia (CIA) and breast cancer (3 arms), sponsored by Medical University of Vienna. Primary endpoint: Hemoglobin response. Started Nov 2011; status: completed.
02
Drugs
ferric carboxymaltosedarbepoetin alfa
03
Conditions
chemotherapy-induced anaemia (CIA)breast cancer
Beyond the preview
Go deeper on 2011-001664-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001664-22.